Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection

被引:156
|
作者
Thorburn, K. [1 ]
机构
[1] Royal Liverpool Childrens Hosp, Dept Paediat Intens Care, Liverpool L12 2AP, Merseyside, England
关键词
VIRAL-INFECTION; US CHILDREN; MORTALITY; BRONCHIOLITIS; INFANTS; INFLUENZA;
D O I
10.1136/adc.2008.139188
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: 600 000 deaths worldwide are estimated to be directly or indirectly attributable to respiratory syncytial virus (RSV). Objectives: To determine: ( 1) the mortality rate; and ( 2) risk factors for death in children with severe RSV infection. Setting: 20-bed, regional, multidisciplinary, tertiary, paediatric intensive care unit (PICU) in a university-affiliated children's hospital. Methods: Cohort study of all children with severe RSV infection covering eight consecutive RSV seasons (1999-2007), using PICU admission as a marker of severity. Results: Of the 406 RSV-positive patients that were admitted to PICU: 98.5% required mechanical ventilation; 35 children died-median age 5.1 months (interquartile range (IQR) 2.4-13.6), length of PICU stay 16 days ( IQR 8-31) and 371 survived-median age 2.5 months ( IQR 1.2-9), length of PICU stay 5 days ( IQR 4-9). The overall PICU RSV mortality was 8.6% with a standardised mortality ratio of 0.76. During the study period 2009 RSV-positive patients were admitted to the children's hospital, giving a hospital RSV mortality rate of 1.7%. Of the deaths, 18 were directly RSV related ( RSV bronchiolitis-related mortality PICU 4.4% and hospital 0.9%) as the patients were still RSV positive when they died and 17 children died from non-pneumonitis causes after becoming RSV negative. All of the RSV deaths had pre-existing medical conditions -chromosomal abnormalities 29%, cardiac lesions 27%, neuromuscular 15%, chronic lung disease 12%, large airway abnormality 9%, and immunodeficiency 9%. Nineteen children (56%) had pre-existing disease in two or more organ systems ( relative risk (RR) 4.38). Predisposing risk factors for death were pre-existing disease ( RR 2.36), cardiac anomaly ( RR 2.98) and nosocomial/hospital-acquired RSV infection ( RR 2.89). There is an interaction effect between pre-existing disease, nosocomial/hospital-acquired RSV infection and mortality ( p < 0.001). Conclusions: Pre-existing disease/comorbidity, in particular multiple pre-existing diseases and cardiac anomaly, is associated with a significantly higher risk of death from severe RSV infection. Nosocomial/hospital-acquired RSV infection is an additional major risk factor for death in children with severe RSV infection.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 50 条
  • [21] Respiratory syncytial virus infection in children with severe motor and intellectual disabilities
    Onoyama, S.
    Hoshina, T.
    Honjo, S.
    Ihara, K.
    Hara, T.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (10) : 1353 - 1357
  • [22] Respiratory syncytial virus infection and invasive meningococcal disease: is there an association?
    Martin C. J. Kneyber
    Adrianus J. van Vught
    European Journal of Pediatrics, 2003, 162 : 352 - 353
  • [23] Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
    Ackerson, Bradley
    Tseng, Hung Fu
    Sy, Lina S.
    Solano, Zendi
    Slezak, Jeff
    Luo, Yi
    Fischetti, Christine A.
    Shinde, Vivek
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (02) : 197 - 203
  • [24] Severe Illnesses Associated With Outbreaks of Respiratory Syncytial Virus and Influenza in Adults
    Zhou, James A.
    Schweinle, Ellen
    Lichenstein, Richard
    Walker, Robert E.
    King, James C.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (05) : 773 - 779
  • [25] Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
    Forbes, Michael L.
    Kumar, Veena R.
    Yogev, Ram
    Wu, Xionghua
    Robbie, Gabriel J.
    Ambrose, Christopher S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2789 - 2794
  • [26] Risk of respiratory syncytial virus infection in infants with congenital cystic lung disease
    Hama, Ikuko
    Takahashi, Shigehiro
    Nakamura, Tomoo
    Ito, Yushi
    Kawasaki, Kazuteru
    Sago, Haruhiko
    PEDIATRICS INTERNATIONAL, 2015, 57 (02) : 253 - 257
  • [27] Human respiratory syncytial virus infection in the pre-clinical calf model
    Cortjens, B.
    de Jong, R.
    Bonsing, J. G.
    van Woensel, J. B. M.
    Bem, R. A.
    Antonis, A. F. G.
    COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2019, 65 : 213 - 218
  • [28] Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012-2018
    Moyes, Jocelyn
    Tempia, Stefano
    Walaza, Sibongile
    Cohen, Adam L.
    Treurnicht, Florette
    Hellferscee, Orienka
    Wolter, Nicole
    von Gottberg, Anne
    Dawood, Halima
    Variava, Ebrahim
    Kahn, Kathleen
    Madhi, Shabir A.
    Cohen, Cheryl
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [29] Paroxysmal supraventricular tachycardia and severe respiratory syncytial virus infection in the neonatal period
    Garrido Ocana, A. I.
    Mora Navarro, D.
    Garcia Soblechero, E.
    Gonzalez Fuentes, C.
    Dominguez Quintero, M. L.
    ANALES DE PEDIATRIA, 2011, 74 (04): : 277 - 278
  • [30] Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies
    Mazur, Natalie, I
    Caballero, Mauricio
    Nunes, Marta C.
    LANCET, 2024, 404 (10458): : 1143 - 1156